PM-1103

N/A

Report date: 2023/04/25 09:11:34

Base Information

Drug NamePM-1103

Drug Alias NamePM1103PM-1103

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionProgrammed death-ligand 1 blockersTumor necrosis factor receptor superfamily member 9 agonists

TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9

Therapy Area/IndicationsN/A

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusIND

Highest Status in ChinaIND

Originator CompaniesBiotheus (Nantong) Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBiotheus (Nantong) Co Ltd

Inactive CompaniesN/A

Active IndicationsN/A

Inactive IndicationsN/A

Other Information

ATC CodeN/A